Background: We assume that besides mismatch repair (MMR) genes, next generation sequencing (NGS) of MMR associated genes could improve detection of driver mutattors and clarify the somatic mutation patterns of subtypes CRC classfied by EMAST and MSI-high. Methods: Extracted from a 1505 CRC cases database,81 cases with MSI-high and EMASTþ,78 cases with EMASTþ and MSS, and 72 cases with MSI-high but EMASTwere identified. The tumor and WBC DNA were applied and got from Biobank of Taipei-Veteran General Hospital afer approval of IRB. The germline and somatic mutations were analyzied with 16-genes NGS (illumina HiSeq2500 system). Results: Totally 284 pathological germline mutations were identified in 161 patients with MSI-high or EMASTþ. The most common gene mutations were EPCAM (17.3%), MSH6 (16.9%), followed by MLH1 (15.2%), and AXIN2(15.2%). Majority of EMAST and MSI resulted from not only MMR dysfunction, but also germline mutations of AXIN2, POLD1 and TGFBR2. After deduction of 284 germline mutations, there were 1,090 somatic mutations in 161 cases with germline mutations, 445 mutations in 70 cases without germline mutations. Tumors with EMASTþ and MSI-high had signifcantly higher mutation number than those of tumors with only EMASTþ or only MSI-high. Besides germline mutations of AXIN2, germline mutations of other genes were similar. With AXIN2 germline mutations, somatic mutation rate was 187.7 6 97.8 mut/MB significantly higher than those of without germline mutations (137.86 84.5 mut/MB p ¼ 0.002). Besides five major MMR genes, Eleven Axin2, eight POLE and six TGFbR2 germline mutations resulted in following MSI-high or EMAST (þ) genotype without other accompany germline mutation. Clinically, patients with germline mutation had significantly higher frequency of proximal tumor location and early stage disease. Conclusions: Our result showed that NGS could enhance detection of familial CRC. Somatic mutation burden might be through MSI or EMAST but not only germline mutation genes themselves. Several genes with germline mutations could explain origin of the familiar CRC. AXIN2 gene deserved to do futher experiment to confirm its role in WNT pathway and as a hypermutator. However, there is a significant discrepancy in response rates (RR) with pembrolizumab and nivolumab (28% to 52%), likely reflecting patient heterogeneity. We sought to determine the RR to PD-1/PD-L1 targeting in a single center setting. Methods: All MCRC patients (pts) with MSI-H tumors (by CLIA certified PCR, IHC, or NGS assays) who were treated at City of Hope with PD-1 or PD-L1 inhibitors starting Jan 2016 were identified. RR and PFS were determined by RECIST 1.1. BRAF status, primary tumor location, and metastatic sites were collected on all pts. TMB as determined by FoundationOneV R on 0.83-1.1 megabases (Mb) of sequenced DNA was collected, when available.
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Results: 17 pts with MSI-H tumors were identified (16 treated with pembrolizumab and 1 with darvulumab). Pts characteristics were: males (10, 59%), age (median 53.7 years, range 33-78), BRAF mutant (6, 35%), right sided (11, 65%), and liver-sparing (8, 47%). 7 (41%) had an objective response, 2 (12%) had stable disease. The median PFS was 9.97 months (mo), and the 6 and 12 mo PFS rates were 53% and 35%, respectively. TMB was available for 9 MSI-H cases (range 8 -73 mutations/Mb): 1 CR (TMB 73), 1 PR (TMB 71), and 1 SD (TMB 31), and 6 PD (TMB: 6, 13, 16, 18, 25, 36) . We categorized our patients based on the lowest 10% (TMB < 23.5) and 25% (TMB < 33.06) TMB cut points identified from a large Foundation Medicine database of MSI-H MCRC. All 4/4 patients in the lowest TMB decile and 5/6 in the lowest TMB quartile experienced PD. On univariate analysis, only hepatic metastases (p ¼ 0.01) and low TMB (p ¼ 0.02) were associated with poor PFS.
Conclusions: A substantial percentage of pts with MSI-H tumors will progress with PD-1/PD-L1 inhibitors; these patients appear to be enriched for a low TMB status and hepatic metastases. Additional studies should explore TMB as a predictive marker of response to checkpoint inhibition in MSI-H CRC. Compared with PCR, IHC method is more economical, convenient for clinical operations. When the 4 repair proteins were without missing detected by IHC, it can be diagnosed as MSS / MSI-L, further PCR was not necessary, and when any repair protein is found to be deficient, PCR detection was needed to determine whether there existed MSI. Our conclusion will save a lot of time and cost for clinical work. Background: Immune checkpoint inhibitors (ICKi) have been approved for patients with metastatic colorectal cancer (mCRC) displaying MSI/dMMR (microsatellite instability, defective mismatch repair). We aimed to evaluate the accuracy of standard immunohistochemistry and PCR methods for the detection of MSI/dMMR in mCRC in routine clinical practice. Methods: The study was performed on a multicenter retrospective cohort of mCRCs previously determined as MSI and/or dMMR by local assessment and on a prospective, single center cohort of patients included in ICKi trials based on positive MSI and/or dMMR status previously determined by the originating institutes. We re-assessed dMMR and MSI status in our specialized diagnostic center using immunohistochemistry (antibodies directed against MLH1, MSH2, MSH6 and PMS2), and pentaplex PCR (BAT-25, . The positive predictive value (PPV) of local assessment was the primary objective of the study. Detection rate (i.e. conclusive result) and sensitivity of immunohistochemistry and PCR by central review were evaluated. 
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